Efficacy and cost-utility of eHealth application 'Oncokompas' for patients with incurable cancer.

Completed

Conditions: oncologische aandoeningen
cancer
malignancies

Registration Number: NL-OMON48895

Lead Sponsor: Vrije Universiteit

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 136

Inclusion Criteria

Inclusion criteria of the RCT:
- Incurable cancer; no curative treatment options;
- A prognosis of at least 3 months;
- Awareness of the incurability of the cancer.

Additional criteria of the PAMQOL-study:
For the qualitative study additional inclusion criteria are that a patient must
have completed the RCT and gave his/her permission on the informed consent form
of the RCT that he/she could be approached for the follow-up study.

Exclusion Criteria

- Not having access to the internet and not having an e-mail address;
- Severe cognitive impairments;
- Psychotic behaviour (delusions and hallucinations);
- Poor understanding of the Dutch language (and thereby not able to complete a
Dutch questionnaire);
- Younger than 18 years;
- Patients too ill to participate;
- Not willing to participate;
- No informed consent;
- Patients who participated in the randomized controlled trial of the
ICT4CANCER project (as a cancer survivor), but who are now diagnosed with
incurable cancer;
- E-mail address of patient is already registered in Oncokompas (this means
that this patient is familiar with using Oncokompas);
- Patients of which their physician/nurse thinks participation in another study
will be too much of a burden.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary outcome measue is patient activation (PAM).</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary outcomes are general self-efficacy (GSE), quality of life (EORTC<br /><br>QLQ-C15-PAL). To investigate the cost-utility we will use different cost<br /><br>questionnaires (iMCQ and iPCQ) and the EQ-5D.</p><br>